Together, these findings suggest that REGγ is highly expressed in pan-KRAS–mutant tumors and indicate that REGγ may be an independent risk factor or a vulnerability factor in patients with such cancers, potentially impacting malignancy and patient prognosis. The gene discussed is KRAS; the disease is cancer.